Featured Story | By Nick Paul Taylor President Donald Trump is considering fast-tracking the authorization of AstraZeneca’s COVID-19 vaccine to ensure a jab is available in time for the November election, according to the Financial Times. The mooted plan is to allow AstraZeneca to gain emergency use authorization on the basis of a 10,000-subject U.K. clinical trial. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus Novartis’ experimental PD-1 blocker came up short in a phase 3 study combining it with its melanoma-fighting duo Tafinlar and Mekinist. Tafinlar, a BRAF inhibitor, and Mekinist, a MEK inhibitor, are already approved to treat melanoma patients with a specific BRAF mutation, but Novartis thought adding a checkpoint inhibitor might help it work even better. read more By Nick Paul Taylor Bristol Myers Squibb has struck a deal to buy Forbius for its portfolio of TGF-beta inhibitors. The takeover will give Bristol Myers control of a clinical-phase inhibitor of TGF-beta 1 and 3 that Forbius is developing to increase the activity of immune checkpoint inhibitors. read more Sponsored By: Cytiva The efficacy of TIL therapies depends on how the original tumor samples are collected, harvested, and processed. read more By Phil Taylor Billions of research dollars have gone into discovering the underlying mechanisms in Alzheimer's disease and seeking drugs that can disrupt the pathogenic steps that lead to the destruction of neurons, but it’s a hugely long and expensive process. read more By Amirah Al Idrus On the heels of a Big Pharma deal worth up to $500 million, Yumanity Therapeutics is merging its way onto Wall Street. The neuro-focused biotech is joining up with Proteostasis, which once planned to move a cystic fibrosis drug into the clinic this year but is now looking for someone to buy its pipeline. read more By Ben Adams Singapore-based Aslan Pharmaceuticals is hitting go again on its stalled dermatitis study. read more By Amirah Al Idrus Drugs for post-traumatic stress disorder don’t work for everyone. EmpathBio, ATAI Life Sciences’ latest company, is looking to fill that gap with treatments based on the “party drug” MDMA in hopes they will work better as add-ons for patients with PTSD who are undergoing psychotherapy than antidepressants, such as Zoloft and Paxil, do. read more By Conor Hale AstraZeneca has enlisted RenalytixAI to help it develop precision medicine strategies for managing patients with chronic diseases of the cardiovascular system, kidneys and metabolism. read more By Arlene Weintraub Pitt researchers demonstrated that pigs can grow functioning auxiliary livers in their abdominal lymph nodes after their own hepatocytes are isolated and injected into them. Startup LyGenesis is working to bring the method into human clinical trials later this year. read more By Eric Sagonowsky Hospitalized COVID-19 patients in the U.S. have another treatment option in the U.S. after the FDA’s emergency authorization for convalescent plasma on Sunday. But the decision prompted pushback from experts who questioned the data and wondered whether the FDA is acting under pressure from President Donald Trump. read more Enrollment Showcase | Presented by: Biotility Taught by experienced professionals, Biotility’s online short courses provide the knowledge and practical skills valued by the bioscience industry. Enhance your career through coursework in one of our certificate pathways, including Document Management, Operations Management, and Quality Management. Learn more. |
| |
|---|
|
Resources Sponsored by: LexisNexis Risk Solutions Traditionally, pharma companies use a combination of prescription data & internal sales reports to look for potential buyers. Such practice provides only a LIMITED VIEW without competitor information. Sponsored by: Optum Download the whitepaper by Optum to see how novel data platforms can uncover hidden insights on medication adherence helping life sciences companies maximize product utilization. Sponsored by: Oracle Health Sciences Patient-facing digital technologies are playing an important role in clinical trials for new drugs and medical devices, to the point where conducting virtual trials is becoming mainstream. But terms like remote trials, direct-to-patient trials, hybrid trials, decentralized trials, and more all add to the confusion of what makes a trial "virtual." Sponsored by: Oracle Health Sciences The research conducted here is to help understand and solve the top challenges in clinical operations, to remove barriers that are slowing down our ability to bring new drugs to market as quickly as possible to patients waiting in need. Sponsored by: Thermo Fisher Scientific How to select the right dosage form for your Phase I clinical supply. Sponsored by: Thermo Fisher Scientific Quality by Design (QbD) reduces risk within drug development, while bringing therapies to market quicker. Sponsored by: Evotec Two informative webcasts will present practical and methodological approaches to preclinical drug abuse liability assessment Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Acorn AI by Medidata, a Dassault Systèmes company Case Study: Oncology-focused pharmaceutical company strengthens product launch by identifying hundreds of high-value physicians with Acorn AI. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: PRA Health Sciences Drug developers and stakeholders must find ways to collaborate, rather than compete, as the RACE Act prompts the need for more pediatric research. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
.jpg)
